Wedbush Keeps Their Buy Rating on Catabasis Pharmaceuticals

In a report issued on May 10, Liana Moussatos from Wedbush reiterated a Buy rating on Catabasis Pharmaceuticals (NASDAQ: CATB), with a price target of $6. The company’s shares closed yesterday at $1.64.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.8% and a 44.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Miragen Therapeutics Inc.

Currently, the analyst consensus on Catabasis Pharmaceuticals is Moderate Buy and the average price target is $6.50, representing a 296.3% upside.

In a report issued on May 10, Oppenheimer also assigned a Buy rating to the stock with a $7 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.78 and a one-year low of $1.09. Currently, Catabasis Pharmaceuticals has an average volume of 962.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Catabasis Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of therapeutics for the treatment of cardiovascular, metabolic and inflammatory diseases.